1 - 25 of 15
Number of results to display per page
TitleCreatorRelation Is Part Of
1 Gene Mediated Therapy for LHONJohn Guy, MDNANOS 2007: Novel Approaches to Treatment of Neuro-Ophthalmic Diseases: Part II: Neuroprotection and Other Methods for Salvaging Visual Function
2 Gene Therapy - Evolution and Therapeutic Applications (PDF)Patrick Yu-Wai-ManNANOS Annual Meeting 2020: New Treatments in Neuro-Ophthalmology-2020 Trends
3 Gene Therapy - Evolution and Therapeutic Applications (Slides)Patrick Yu-Wai-ManNANOS Annual Meeting 2020: New Treatments in Neuro-Ophthalmology - 2020 Trends
4 Gene Therapy for Leber Congenital AmaurosisWilliam Hauswirth; Jijing Pang; Sanford BoyeNANOS 2007: Novel Approaches to Treatment of Neuro-Ophthalmic Diseases: Part II: Neuroprotection and Other Methods for Salvaging Visual Function
5 Gene Therapy to Abolish Congenital Nystagmus in RPE65-Deficient CaninesL. F. Dell'Osso, PhD; J. B. Jacobs, PhD; R. W. Hertle, MD; J. Bennett, MD, PhD; G. Acland, DVMNANOS 2003: Scientific Platforms Presentations II
6 Genetic Manipulation for Inherited Neuodegenerative Diseases - Myth or Reality? (slideshow)Patrick Yu-Wai-ManNANOS Annual Meeting 2016: Hot Topics - Today and Tomorrow
7 Genetic Manipulation for Inherited Neurodegenerative Diseases - Myth or Reality? (.pdf)Patrick Yu-Wai-ManNANOS Annual Meeting 2016: Hot Topics - Today and Tomorrow
8 Leber Hereditary Optic Neuropathy G11778A Gene Therapy Clinical Trial: Serial Pretreatment Evaluation from Baseline to Two YearsByron Lam; John Guy; Fawzi Abukhalil; Feuer William; Potyra Aroucha; Alexis MoranteNANOS 2012: Platform Presentation
9 Leber Hereditary Optic Neuropathy G11778A Gene Therapy Clinical Trial: Stability of Clinical Parameters in Preparatory Phase Based on Onset of Visual LossByron L. Lam; John R. Guy; William J. Feuer; Vittorio Porciatti; Ruth Vandenbroucke; Joyce C. SchiffmanNANOS 2013: Platform Presentations (Session II)
10 Leber Hereditary Optic Neuropathy G11778A Gene Therapy Clinical Trial: Stability of Clinical Parameters in Preparatory Phase Based on Onset of Visual LossByron L. Lam; John R. Guy; William J. Feuer; Vittorio Porciatti; Ruth Vandenbroucke; Joyce C. SchiffmanNANOS 2013: Platform Presentations (Session II)
11 Leber Hereditary Optic Neuropathy Gene Therapy Clinical Trial for G11778A MutationByron Lam; John Guy; Vittorio Porciatti; Abukhalil Fawzi; Morante Alexis; Feuer WilliamNANOS 2010: Poster Presentations
12 Leber Hereditary Optic Neuropathy Gene Therapy Clinical Trial for G11778A MutationByron Lam; John Guy; Vittorio Porciatti; Abukhalil Fawzi; Morante Alexis; Feuer WilliamNANOS 2010: Poster Presentations
13 Leber Hereditary Optic Neuropathy Gene Therapy Clinical Trial for G11778A Mutation: Serial Pretreatment Evaluation from Baseline to One YearByron Lam; John Guy; Fawzi Abukhalil; Vittorio Porciatti; William Feuer; Alexis MoranteNANOS 2011: Poster Presentations
14 Safety/Acuity Outcomes 96-Weeks Post-Treatment with rAAV2/2-ND4; Gene Therapy for ND4 LHON: a Phase I/II TrialBarrett Katz; Catherine Vignal; Celine Bouquet; Nitza Thomasson; Ann Galy; Serge Fitoussi; Jose SahelNANOS Annual Meeting 2018: Scientific Platform, Session I
15 Stem Cells, Gene Therapy and the Neuro-OphthalmologistJeffrey Bennett, MD, PhDNANOS 2011: Hot Topics (Controversies)
1 - 25 of 15